An article reported on,discusses topiramate, a medication increasingly prescribed for a number of neurological and non-neurological indications. Topiramate-treated patients are at risk for nephrolithiasis (kidney stones) due to hypocitraturia and high urine pH. However, the prevalence of symptomatic stone disease in TPM users is generally perceived to be low. Several studies assessing topiramate users with an average daily dose of 300 mg. suggest the prevalence of symptomatic nephrolithiasis to be 1.10% to 10.7%. In a subset of topiramate-treated adult patients with no history of symptomatic stone disease, the prevalence of asymptomatic nephrolithiasis detected by CT scan was 20%. In these studies, females consist of 79% of kidney stone sufferers, and men just over 20%. These studies suggest the prevalence of kidney stone sufferers with long-term topiramate use is higher than reported in short-term studies

Pin It on Pinterest